4 Results for "

PLS240

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "PLS240" in MCE Product Catalog:

Cat. No.: HY-109106A
CAS No.: 2052969-18-1
Purity:  99.91%
Synonyms: SK-1403; AJT240; PLS240
Target:  

CaSR

Research Areas:  

Endocrinology

Upacicalcet sodium is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet sodium reduces serum intact parathyroid hormone (iPTH) and serum Ca 2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet sodium sodium improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet sodium sodium inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet sodium is useful for studying SHPT .
loading...
    loading...
Cat. No.: HY-109106
CAS No.: 1333218-50-0
Synonyms: SK-1403 free acid; AJT240 free acid; PLS240 free acid
Target:  

CaSR

Research Areas:  

Endocrinology

Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .
loading...
    loading...
Cat. No.: HY-109106AR
CAS No.: 2052969-18-1
Synonyms: SK-1403 (Standard); AJT240 (Standard); PLS240 (Standard)
Research Areas:  

Endocrinology

Upacicalcet sodium (Standard) is the analytical standard of Upacicalcet (sodium) (HY-109106A). This product is intended for research and analytical applications. Upacicalcet sodium is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet sodium reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet sodium sodium improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet sodium sodium inhibits cortical pore formation and reduces bone fibrosis in rats with chronic Kidney disease (CKd). Upacicalcet sodium is useful for studying SHPT .
loading...
    loading...
Cat. No.: HY-109106B
CAS No.: 2649575-19-7
Purity:  ≥95.0%
Synonyms: (Rac)-SK-1403 free acid; (Rac)-AJT240 free acid; (Rac)-PLS240 free acid
Target:  

CaSR

Research Areas:  

Endocrinology

(Rac)-Upacicalcet is the racemate of Upacicalcet (HY-109106). Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .
loading...
    loading...